IGF-1 LR3, also written as Long R3 IGF-1, is a synthetic analog of insulin-like growth factor 1 whose documented use is almost entirely as a laboratory reagent and a biomanufacturing supplement, not as an approved medicine. It is sold under research-use-only terms, has no FDA approval for human therapy, and is banned in sport by anti-doping authorities. Human clinical data are absent, so every claim about its effects in people rests on cell-culture work, animal studies, and mechanistic reasoning rather than controlled trials.
IGF-1 LR3 is an 83-amino-acid research-use-only analog of IGF-1 with no FDA approval for human use, documented almost entirely as a growth additive in serum-free cell culture and as a tool compound in animal research.
IGF-1 LR3 is native IGF-1 rebuilt with two deliberate edits, and one of them carries almost all of the functional weight. Native human IGF-1 is a 70-residue single-chain protein folded like proinsulin; the analog swaps the glutamate at position 3 for an arginine and fuses a 13-residue extension onto the N-terminus, bringing it to 83 residues. The position-3 substitution is the one that matters, since it weakens the grip of the IGF binding proteins that normally hold IGF-1 in reserve.
| Property | Native IGF-1 | IGF-1 LR3 |
|---|---|---|
| Chain length | 70 amino acids | 83 amino acids |
| Molecular weight | ~7.6 kDa | ~9.1 kDa |
| Position 3 residue | Glutamate | Arginine |
| N-terminus | Native sequence | 13-residue extension |
| Binding-protein affinity | High, held in reserve | Reduced, stays free |
IGF-1 LR3 extends native IGF-1 to 83 amino acids and about 9.1 kilodaltons through a position-3 glutamate-to-arginine substitution plus a 13-residue N-terminal extension, and the position-3 change is what reduces its binding-protein affinity.
The extra potency is a binding-protein evasion story, not a stronger grip on the receptor. In serum and in the body, six IGF binding proteins capture most native IGF-1 and leave only a small free fraction able to signal, and the position-3 substitution plus the N-terminal extension disrupt the surface those proteins latch onto. More free peptide reaches the receptor, and it stays active longer because nothing is pulling it out of solution.
IGF-1 LR3 owes its enhanced, longer-lasting activity to escaping the six IGF binding proteins rather than to tighter receptor binding, leaving a larger free pool to drive PI3K-Akt and Ras-MAPK signaling through the type 1 IGF receptor.
The whole value of IGF-1 LR3 in culture is that it delivers a strong growth signal at very low doses without being neutralized by binding proteins present in media or secreted by the cells themselves. Formulators report using nanogram-per-milliliter amounts for a consistent proliferative and pro-survival effect, where native IGF-1 at the same dose would be partly sequestered and less predictable.
In serum-free and chemically defined media, IGF-1 LR3 delivers a consistent growth signal at roughly 10 to 100 nanograms per milliliter, a fraction of the microgram-per-milliliter insulin dose used to hit the same receptor.
Beyond the bioreactor, IGF-1 LR3 serves as a tool compound in animal work where a durable IGF-1 receptor signal is wanted. Its resistance to binding proteins gives a cleaner, longer dose-response than native IGF-1, which is quickly buffered in vivo, so an observed effect can be attributed more confidently to receptor engagement.
IGF-1 LR3's use in rodent studies of growth, muscle anabolism, and metabolic signaling remains firmly preclinical, and findings in animals do not establish human efficacy or safety because dosing does not scale across species and the analog does not behave like endogenous IGF-1.
IGF-1 LR3 is not an approved medicine. No major regulator, including the United States Food and Drug Administration, has authorized it as a human therapeutic, and it exists in commerce as a research reagent and manufacturing input rather than a drug. It is sold under research-use-only terms, labeled explicitly as not for human or veterinary use.
IGF-1 LR3 has no FDA approval for human or veterinary use, is sold strictly under research-use-only terms, and is banned at all times in tested sport under the World Anti-Doping Agency prohibited list.
The safety picture is built from the pharmacology of IGF-1 signaling and from animal data, not from human trials of this specific analog, so every point below is inference rather than established human evidence. Potent, sustained receptor activation overlaps with insulin-like metabolic effects, which is why the documented risks track the strength and duration of exposure.
IGF-1 LR3 has never been studied in controlled human trials, so hypoglycemia, the theoretical proliferative and overgrowth concerns, and research-chemical quality variation are documented as mechanistic and animal-based inference with no established human safety profile, validated dose, or monitoring standard.
Educational use only. This article describes what the published scientific and clinical literature reports about IGF-1 LR3. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
